There are many different types of dry eye disease clinics in North America. No matter what type of practice you might have, it is highly likely that practicing your subspecialty became measurably easier in 2023.
Whether you treat dry eye disease (DED) and associated clinical entities such as blepharitis and meibomian gland dysfunction (MGD) on purpose or only when you cannot avoid them, the arrival of Miebo (perfluorohexyloctane ophthalmic solution, Bausch + Lomb) and Xdemvy (lotilaner ophthalmic solution 0.25%, Tarsus Pharmaceuticals) in 2023 instantly made it easier to achieve success (Read more...)